A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

A new study from researchers at Wake Forest University School of Medicine is shedding light on how scientific evidence and the uncertainty surrounding three unproven therapeutics were portrayed by ...

In 2020, then-President Donald Trump said he had been taking hydroxychloroquine to prevent a COVID-19 infection despite warnings over side effects.

A new study from UCLA Health suggests COVID-19 vaccines may protect patients from severe kidney damage. The study found hospitalized COVID-19 patients were less likely to have severe kidney damage if ...

Single doses of 150 milligrams (mg), 300 mg, and 450 mg provided 58%, 61%, and 76% protection from symptomatic flu, ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem ...

In a Phase 3 study, the company’s mRNA-1010 flu ... to daily life and work After consulting the Food and Drug Administration, Moderna withdrew its application last month for a dual flu and COVID-19 ...

Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.